{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"The primary objective of this study was to establish the rate of acute GVHD following prophylactic cellular immunotherapy after allogeneic hematopoietic stem cell therapy using low intensity conditioning for high-risk hematological malignancies. Glucksberg staging was used for organ grading of GVHD. Clinical GVHD was assessed as follows:\n\nGrade 0: No stage 1-4 of any organ Grade 1: Stage 1-2 rash and no liver or gut involvement Grade 2: Stage 3 rash, or Stage 1 liver involvement, or Stage 1 GI Grade 3: Stage 0-3 skin with Stage 2-3 liver, or Stage 2-4 GI Grade 4: Stage 4 skin rash, or Stage 4 liver involvement","groups":[{"description":"Reduced intensity conditioning consisting of Busulfan and Fludarabine(fludarabine 150 mg/m2 IV, busulfan 6 mg/kg IV, total lymphoid irradiation 2 Gy), followed by a rapid immunosuppressive taper of Tacrolimus (0.06 mg/kg q12h, PO, Days -7 to +28), Methotrexate (5 mg/m2, IV, Days +1, +3, +6, +11) and Mycophenolate Mofetil (10 mg/kg every 8 hours, PO, Days -6 to +7).","id":"OG000","title":"Immunosuppression Taper"}],"paramType":"NUMBER","populationDescription":"54 patients were enrolled however 9 patients did not receive planned donor lymphocyte infusion. 45 patients were analyzed.","reportingStatus":"POSTED","timeFrame":"100 days","title":"Percentage of Participants With Acute Graft Versus Host Disease (GVHD) Grades 2-4","type":"PRIMARY","unitOfMeasure":"percentage of participants"}